{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T03:24:23Z","timestamp":1794367463908,"version":"4.9.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,6,22]],"date-time":"2018-06-22T00:00:00Z","timestamp":1529625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/J01186X\/1"],"award-info":[{"award-number":["MR\/J01186X\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["G0901321"],"award-info":[{"award-number":["G0901321"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/M006301\/1"],"award-info":[{"award-number":["MR\/M006301\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004963","name":"EC | Seventh Framework Programme","doi-asserted-by":"publisher","award":["FP7-PEOPLE-2012-ITN-316716"],"award-info":[{"award-number":["FP7-PEOPLE-2012-ITN-316716"]}],"id":[{"id":"10.13039\/501100004963","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["WT096002\/Z\/11\/Z"],"award-info":[{"award-number":["WT096002\/Z\/11\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1038\/s41380-018-0104-7","type":"journal-article","created":{"date-parts":[[2018,6,22]],"date-time":"2018-06-22T08:22:42Z","timestamp":1529655762000},"page":"873-882","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":142,"title":["Glutathione and glutamate in schizophrenia: a 7T MRS study"],"prefix":"10.1038","volume":"25","author":[{"given":"Jyothika","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth B.","family":"Liddle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina C.","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Palaniyappan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma L.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si\u00e2n E.","family":"Robson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Simmonite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Fiesal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Z.","family":"Katshu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayaz","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Skelton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos G.","family":"Christodoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Brookes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter F.","family":"Liddle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,22]]},"reference":[{"key":"104_CR1","doi-asserted-by":"crossref","unstructured":"Abi-Dargham A, Grace A. Dopamine and schizophrenia. In: Weinberger DR, Harrison P, editors. Schizophrenia. 3rd ed. Oxford: Wiley-Blackwell; 2011. p. 413\u201332.","DOI":"10.1002\/9781444327298.ch20"},{"key":"104_CR2","doi-asserted-by":"crossref","unstructured":"Krystal JH, Moghaddam B. Contributions of glutamate and GABA systems to the neurobiology and treatment of schizophrenia. In: Weinberger DR, Harrison P, editors. Schizophrenia. 3rd ed. Oxford: Wiley-Blackwell; 2011. p. 433\u201361. .","DOI":"10.1002\/9781444327298.ch21"},{"key":"104_CR3","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1093\/schbul\/sbs075","volume":"38","author":"B Moghaddam","year":"2012","unstructured":"Moghaddam B, Krystal JH. Capturing the angel in \u201cangel dust\u201d: twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans. Schizophr Bull. 2012;38:942\u20139.","journal-title":"Schizophr Bull"},{"key":"104_CR4","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/00002826-200101000-00008","volume":"24","author":"SI Deutsch","year":"2001","unstructured":"Deutsch SI, Rosse RB, Schwartz BL, Mastropaolo J. A revised excitotoxic hypothesis of schizophrenia: therapeutic implications. Clin Neuropharmacol. 2001;24:43\u20139.","journal-title":"Clin Neuropharmacol"},{"key":"104_CR5","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/nyas.12547","volume":"1338","author":"W Hu","year":"2015","unstructured":"Hu W, MacDonald ML, Elswick DE, Sweet RA. The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies. Ann NY Acad Sci. 2015;1338:38\u201357.","journal-title":"Ann NY Acad Sci"},{"key":"104_CR6","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.schres.2008.06.016","volume":"104","author":"J Shi","year":"2008","unstructured":"Shi J, Gershon ES, Liu C. Genetic associations with schizophrenia: meta-analyses of 12 candidate genes. Schizophr Res. 2008;104:96\u2013107.","journal-title":"Schizophr Res"},{"key":"104_CR7","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/2045125311400779","volume":"1","author":"JM Stone","year":"2011","unstructured":"Stone JM. Glutamatergic antipsychotic drugs: a new dawn in the treatment of schizophrenia? Ther Adv Psychopharmacol. 2011;1:5\u201318.","journal-title":"Ther Adv Psychopharmacol"},{"key":"104_CR8","doi-asserted-by":"crossref","first-page":"396","DOI":"10.47102\/annals-acadmedsg.V38N5p396","volume":"38","author":"SJ Wood","year":"2009","unstructured":"Wood SJ,Y\u00fccel M,Pantelis C,Berk M, Neurobiology of schizophrenia spectrum disorders: the role of oxidative stress. Ann Acad Med Singapore. 2009;38:396","journal-title":"Ann Acad Med Singapore"},{"key":"104_CR9","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.pnpbp.2009.06.018","volume":"33","author":"M Raffa","year":"2009","unstructured":"Raffa M, Mechri A, Othman LB, Fendri C, Gaha L, Kerkeni A. Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33:1178\u201383.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"104_CR10","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1155\/2006\/248387","volume":"22","author":"JK Yao","year":"2006","unstructured":"Yao JK, Leonard S, Reddy R. Altered glutathione redox state in schizophrenia. Dis Markers. 2006;22:83\u201393.","journal-title":"Dis Markers"},{"key":"104_CR11","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1017\/S1461145710000805","volume":"14","author":"JW Gawryluk","year":"2011","unstructured":"Gawryluk JW, Wang JF, Andreazza AC, Shao L, Young LT. Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. Int J Neuropsychopharmacol. 2011;14:123\u201330.","journal-title":"Int J Neuropsychopharmacol"},{"key":"104_CR12","doi-asserted-by":"crossref","first-page":"16621","DOI":"10.1073\/pnas.0706778104","volume":"104","author":"R Gysin","year":"2007","unstructured":"Gysin R, Kraftsik R, Sandell J, Bovet P, Chappuis C, Conus P, et al. Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence. Proc Natl Acad Sci USA. 2007;104:16621\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"104_CR13","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1111\/j.1460-9568.2006.04974.x","volume":"24","author":"M Persson","year":"2006","unstructured":"Persson M, Sandberg M, Hansson E, R\u00f6nnb\u00e4ck L. Microglial glutamate uptake is coupled to glutathione synthesis and glutamate release. Eur J Neurosci. 2006;24:1063\u201370.","journal-title":"Eur J Neurosci"},{"key":"104_CR14","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1111\/j.1471-4159.2007.04487.x","volume":"101","author":"SW Barger","year":"2007","unstructured":"Barger SW, Goodwin ME, Porter MM, Beggs ML. Glutamate release from activated microglia requires the oxidative burst and lipid peroxidation. J Neurochem. 2007;101:1205\u201313.","journal-title":"J Neurochem"},{"key":"104_CR15","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0165-0173(97)00045-3","volume":"25","author":"JS Bains","year":"1997","unstructured":"Bains JS, Shaw CA. Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-mediated neuronal death. Brain Res Brain Res Rev. 1997;25:335\u201358.","journal-title":"Brain Res Brain Res Rev"},{"key":"104_CR16","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1523\/JNEUROSCI.14-05-02924.1994","volume":"14","author":"A Volterra","year":"1994","unstructured":"Volterra A, Trotti D, Tromba C, Floridi S, Racagni G. Glutamate uptake inhibition by oxygen free radicals in rat cortical astrocytes. J Neurosci. 1994;14:2924\u201332.","journal-title":"J Neurosci"},{"key":"104_CR17","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nrn.2015.19","volume":"17","author":"GE Hardingham","year":"2016","unstructured":"Hardingham GE, Do KQ. Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis. Nat Rev Neurosci. 2016;17:125\u201334.","journal-title":"Nat Rev Neurosci"},{"key":"104_CR18","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.neuroscience.2005.10.014","volume":"137","author":"P Steullet","year":"2006","unstructured":"Steullet P, Neijt HC, Cu\u00e9nod M, Do KQ. Synaptic plasticity impairment and hypofunction of NMDA receptors induced by glutathione deficit: relevance to schizophrenia. Neuroscience. 2006;137:807\u201319.","journal-title":"Neuroscience"},{"key":"104_CR19","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/nn2071","volume":"11","author":"S Papadia","year":"2008","unstructured":"Papadia S, Soriano FX, L\u00e9veill\u00e9 F, Martel MA, Dakin KA, Hansen HH, et al. Synaptic NMDA receptor activity boosts intrinsic antioxidant defences. Nat Neurosci. 2008;11:476\u201387.","journal-title":"Nat Neurosci"},{"key":"104_CR20","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms7761","volume":"6","author":"PS Baxter","year":"2015","unstructured":"Baxter PS, Bell KF, Hasel P, Kaindl AM, Fricker M, Thomson D, et al. Synaptic NMDA receptor activity is coupled to the transcriptional control of the glutathione system. Nat Commun. 2015;6:6761.","journal-title":"Nat Commun"},{"key":"104_CR21","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.1046\/j.1460-9568.2000.00229.x","volume":"12","author":"KQ Do","year":"2000","unstructured":"Do KQ, Trabesinger AH, Kirsten-Kr\u00fcger M, Lauer CJ, Dydak U, Hell D, et al. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci. 2000;12:3721\u20138.","journal-title":"Eur J Neurosci"},{"key":"104_CR22","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1093\/schbul\/sbw038","volume":"42","author":"L Xin","year":"2016","unstructured":"Xin L, Mekle R, Fournier M, Baumann PS, Ferrari C, Alameda L, et al. Genetic polymorphism associated prefrontal glutathione and its coupling with brain glutamate and peripheral redox status in early psychosis. Schizophr Bull. 2016;42:1185\u201396.","journal-title":"Schizophr Bull"},{"key":"104_CR23","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/mp.2014.88","volume":"20","author":"A Monin","year":"2015","unstructured":"Monin A, Baumann PS, Griffa A, Xin L, Mekle R, Fournier M, et al. Glutathione deficit impairs myelin maturation: relevance for white matter integrity in schizophrenia patients. Mol Psychiatry. 2015;20:827\u201338.","journal-title":"Mol Psychiatry"},{"key":"104_CR24","doi-asserted-by":"crossref","first-page":"e1944","DOI":"10.1371\/journal.pone.0001944","volume":"3","author":"D Matsuzawa","year":"2008","unstructured":"Matsuzawa D, Obata T, Shirayama Y, Nonaka H, Kanazawa Y, Yoshitome E, et al. Negative correlation between brain glutathione level and negative symptoms in schizophrenia: a 3T 1H-MRS study. PLoS ONE. 2008;3:e1944.","journal-title":"PLoS ONE"},{"key":"104_CR25","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s10334-005-0012-0","volume":"18","author":"M Terpstra","year":"2005","unstructured":"Terpstra M, Vaughan TJ, Ugurbil K, Lim KO, Schulz SC, Gruetter R. Validation of glutathione quantitation from STEAM spectra against edited 1H NMR spectroscopy at 4T: application to schizophrenia. MAGMA. 2005;18:276\u201382.","journal-title":"MAGMA"},{"key":"104_CR26","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.schres.2016.02.017","volume":"172","author":"AS Brandt","year":"2016","unstructured":"Brandt AS, Unschuld PG, Pradhan S, Lim IA, Churchill G, Harris AD, et al. Age-related changes in anterior cingulate cortex glutamate in schizophrenia: a 1H MRS Study at 7 Tesla. Schizophr Res. 2016;172:101\u20135.","journal-title":"Schizophr Res"},{"key":"104_CR27","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.nbd.2008.11.018","volume":"33","author":"SJ Wood","year":"2009","unstructured":"Wood SJ, Berger GE, Wellard RM, Proffitt TM, McConchie M, Berk M, et al. Medial temporal lobe glutathione concentration in first episode psychosis: a 1H-MRS investigation. Neurobiol Dis. 2009;33:354\u20137.","journal-title":"Neurobiol Dis"},{"key":"104_CR28","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1002\/jnr.21444","volume":"85","author":"MC McKenna","year":"2007","unstructured":"McKenna MC. The glutamate-glutamine cycle is not stoichiometric: fates of glutamate in brain. J Neurosci Res. 2007;85:3347\u201358.","journal-title":"J Neurosci Res"},{"key":"104_CR29","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/schbul\/sbr069","volume":"39","author":"A Marsman","year":"2013","unstructured":"Marsman A, van den Heuvel MP, Klomp DW, Kahn RS, Luijten PR, Hulshoff Pol HE. Glutamate in schizophrenia: a focused review and meta-analysis of 1H-MRS studies. Schizophr Bull. 2013;39:120\u20139.","journal-title":"Schizophr Bull"},{"key":"104_CR30","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1001\/jamapsychiatry.2016.0442","volume":"73","author":"K Merritt","year":"2016","unstructured":"Merritt K, Egerton A, Kempton MJ, Taylor MJ, McGuire PK. Nature of glutamate alterations in schizophrenia: a meta-analysis of proton magnetic resonance spectroscopy studies. JAMA Psychiatry. 2016;73:665\u201374.","journal-title":"JAMA Psychiatry"},{"key":"104_CR31","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2016.239","volume":"6","author":"LM Rowland","year":"2016","unstructured":"Rowland LM, Pradhan S, Korenic S, Wijtenburg SA, Hong LE, Edden RA, et al. Elevated brain lactate in schizophrenia: a 7T Magnetic Resonance Spectroscopy Study. Transl Psychiatry. 2016;6:e967.","journal-title":"Transl Psychiatry"},{"key":"104_CR32","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.nicl.2014.10.005","volume":"6","author":"A Marsman","year":"2014","unstructured":"Marsman A, Mandl RC, Klomp DW, Bohlken MM, Boer VO, Andreychenko A, et al. GABA and glutamate in schizophrenia: a 7T 1H-MRS Study. Neuroimage Clin. 2014;6:398\u2013407.","journal-title":"Neuroimage Clin"},{"key":"104_CR33","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.biopsych.2016.04.007","volume":"81","author":"KN Thakkar","year":"2017","unstructured":"Thakkar KN, R\u00f6sler L, Wijnen JP, Boer VO, Klomp DW, Cahn W, et al. 7T proton magnetic resonance spectroscopy of gamma-aminobutyric acid, glutamate, and glutamine reveals altered concentrations in patients with schizophrenia and healthy siblings. Biol Psychiatry. 2017;81:525\u201335.","journal-title":"Biol Psychiatry"},{"key":"104_CR34","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/jamapsychiatry.2013.3939","volume":"71","author":"JR Bustillo","year":"2014","unstructured":"Bustillo JR, Chen H, Jones T, Lemke N, Abbott C, Qualls C, et al. Increased glutamine in patients undergoing long-term treatment for schizophrenia: a proton magnetic resonance spectroscopy study at 3T. JAMA Psychiatry. 2014;71:265\u201372.","journal-title":"JAMA Psychiatry"},{"key":"104_CR35","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/schbul\/sbv118","volume":"42","author":"E Plitman","year":"2016","unstructured":"Plitman E, de la Fuente-Sandoval C, Reyes-Madrigal F, Chavez S, G\u00f3mez-Cruz G, Le\u00f3n-Ortiz P, et al. Elevated myo-inositol, choline, and glutamate levels in the associative striatum of antipsychotic-naivepatients with first-episode psychosis: a proton magnetic resonance spectroscopy study with implications for glial dysfunction. Schizophr Bull. 2016;42:415\u201324.","journal-title":"Schizophr Bull"},{"key":"104_CR36","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.schres.2008.11.014","volume":"108","author":"SY Tayoshi","year":"2009","unstructured":"Tayoshi SY, Sumitani S, Taniguchi K, Shibuya-Tayoshi S, Numata S, Iga J, et al. Metabolite changes and gender differences in schizophrenia using 3-Tesla proton magnetic resonance spectroscopy (1H-MRS). Schizophr Res. 2009;108:69\u201377.","journal-title":"Schizophr Res"},{"key":"104_CR37","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.pscychresns.2004.08.001","volume":"132","author":"J Th\u00e9berge","year":"2004","unstructured":"Th\u00e9berge J, Al-Semaan Y, Jensen JE, Williamson PC, Neufeld RW, Menon RS, et al. Comparative study of proton and phosphorus magnetic resonance spectroscopy in schizophrenia at 4 Tesla. Psychiatry Res. 2004;132:33\u20139.","journal-title":"Psychiatry Res"},{"key":"104_CR38","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.biopsych.2010.08.024","volume":"69","author":"JR Bustillo","year":"2011","unstructured":"Bustillo JR, Chen H, Gasparovic C, Mullins P, Caprihan A, Qualls C, et al. Glutamate as a marker of cognitive function in schizophrenia: a proton spectroscopic imaging study at 4 Tesla. Biol Psychiatry. 2011;69:19\u201327.","journal-title":"Biol Psychiatry"},{"key":"104_CR39","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1038\/npp.2012.126","volume":"37","author":"NV Kraguljac","year":"2012","unstructured":"Kraguljac NV, Reid MA, White DM, den Hollander J, Lahti AC. Regional decoupling of N-acetyl-aspartate and glutamate in schizophrenia. Neuropsychopharmacology. 2012;37:2635\u201342.","journal-title":"Neuropsychopharmacology"},{"key":"104_CR40","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1038\/npp.2012.113","volume":"37","author":"A Egerton","year":"2012","unstructured":"Egerton A, Brugger S, Raffin M, Barker GJ, Lythgoe DJ, McGuire PK, et al. Anterior cingulate glutamate levels related to clinical status following treatment in first-episode schizophrenia. Neuropsychopharmacology. 2012;37:2515\u201321.","journal-title":"Neuropsychopharmacology"},{"key":"104_CR41","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.schres.2013.12.013","volume":"152","author":"EM Poels","year":"2014","unstructured":"Poels EM, Kegeles LS, Kantrowitz JT, Javitt DC, Lieberman JA, Abi-Dargham A, et al. Glutamatergic abnormalities in schizophrenia: a review of proton MRS findings. Schizophr Res. 2014;152:325\u201332.","journal-title":"Schizophr Res"},{"key":"104_CR42","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.neubiorev.2015.01.007","volume":"51","author":"SA Wijtenburg","year":"2015","unstructured":"Wijtenburg SA, Yang S, Fischer BA, Rowland LM. In vivo assessment of neurotransmitters and modulators with magnetic resonance spectroscopy: application to schizophrenia. Neurosci Biobehav Rev. 2015;51:276\u201395.","journal-title":"Neurosci Biobehav Rev"},{"key":"104_CR43","unstructured":"World Health Organization. ICD-10 classifications of mental and behavioural disorder: clinical descriptions and diagnostic guidelines. Geneva: World Health Organization; 1992."},{"key":"104_CR44","volume-title":"Diagnostic and statistical manual of mental disorders: DSM-IV","author":"American Psychiatric Association.","year":"1994","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV. 4th ed. Washington, DC: American Psychiatric Association; 1994.","edition":"4th ed"},{"key":"104_CR45","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1503\/jpn.100176","volume":"37","author":"L Palaniyappan","year":"2012","unstructured":"Palaniyappan L, Liddle PF. Does the salience network play a cardinal role in psychosis? An emerging hypothesis of insular dysfunction. J Psychiatry Neurosci. 2012;37:17\u201327.","journal-title":"J Psychiatry Neurosci"},{"key":"104_CR46","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.schres.2013.03.028","volume":"147","author":"L Palaniyappan","year":"2013","unstructured":"Palaniyappan L, Crow TJ, Hough M, Voets NL, Liddle PF, James S, et al. Gyrification of Broca\u2019s region is anomalously lateralized at onset of schizophrenia in adolescence and regresses at 2year follow-up. Schizophr Res. 2013;147:39\u201345.","journal-title":"Schizophr Res"},{"key":"104_CR47","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/schbul\/sbs069","volume":"38","author":"DC Javitt","year":"2012","unstructured":"Javitt DC, Zukin SR, Heresco-Levy U, Umbricht D. Has an angel shown the way? Etiological and therapeutic implications of the PCP\/NMDA model of schizophrenia. Schizophr Bull. 2012;38:958\u201366.","journal-title":"Schizophr Bull"},{"key":"104_CR48","unstructured":"WHO Collaborating Centre for Drug Statistics and Methodology. Guidelines for ATC classification and DDD assignment. Oslo, Norway: WHO Collaborating Centre for Drug Statistics and Methodology; 2003."},{"key":"104_CR49","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s10334-007-0102-2","volume":"21","author":"M Poole","year":"2008","unstructured":"Poole M, Bowtell R. Volume parcellation for improved dynamic shimming. MAGMA. 2008;21:31\u201340.","journal-title":"MAGMA"},{"key":"104_CR50","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.neuroimage.2013.04.077","volume":"86","author":"EL Hall","year":"2014","unstructured":"Hall EL, Stephenson MC, Price D, Morris PG. Methodology for improved detection of low concentration metabolites in MRS: optimised combination of signals from multi-element coil arrays. Neuroimage. 2014;86:35\u201342.","journal-title":"Neuroimage"},{"key":"104_CR51","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/mrm.1910300604","volume":"30","author":"SW Provencher","year":"1993","unstructured":"Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med. 1993;30:672\u20139.","journal-title":"Magn Reson Med"},{"key":"104_CR52","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.neuroimage.2008.03.060","volume":"42","author":"H Neeb","year":"2008","unstructured":"Neeb H, Ermer V, Stocker T, Shah NJ. Fast quantitative mapping of absolute water content with full brain coverage. Neuroimage. 2008;42:1094\u2013109.","journal-title":"Neuroimage"},{"key":"104_CR53","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/mrm.20901","volume":"55","author":"C Gasparovic","year":"2006","unstructured":"Gasparovic C, Song T, Devier D, Bockholt HJ, Caprihan A, Mullins PG, et al. Use of tissue water as a concentration reference for proton spectroscopic imaging. Magn Reson Med. 2006;55:1219\u201326.","journal-title":"Magn Reson Med"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41380-018-0104-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41380-018-0104-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41380-018-0104-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T09:02:15Z","timestamp":1693731735000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-018-0104-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,22]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["104"],"URL":"https:\/\/doi.org\/10.1038\/s41380-018-0104-7","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,22]]},"assertion":[{"value":"7 May 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"LP is an employee of Western University, Ontario. He receives book royalties from Oxford University Press and income from the SPMM MRCPsych course. In the last 2 years, his or his spousal pension funds held shares of Shire Inc., and GlaxoSmithKline. He has received travel support to speak at a meeting organized by Magstim Ltd (UK). The remaining authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}